Table 3.
Overall survival data and their relation with other clinical factors.
| Parameters | Median (95% CI, months) | P | |
|---|---|---|---|
| Survival | Overall | 12.03 (7.2–16.8) | |
| Gender | Male | 11.38 (9.0–13.7) | 0.32 |
| Female | 16.51 (7.4–25.5) | ||
| Age | <65 | 15.88 (13.3–18.4) | 0.03 |
| ≥65 | 9.27 (5.1–13.4) | ||
| Smoking | Yes | 17.69 (5.5–29.8) | 0.51 |
| No | 12.03 (7.6–16.4) | ||
| ECOG-PS* | O–1 | 15.88 (7.7–24.0) | <0.01 |
| >1 | 9.93 (4.3–15.5) | ||
| Clinical stage | 2 | 10.95 (0.0–31.7) | 0.07 |
| 3 | 18.58 (8.4–28.7) | ||
| 4 | 11.38 (8.0–14.7) | ||
| Histological type | Epithelial | 12.00 (4.9–19.0) | 0.07 |
| Mixed | 17.69 (5.0–30.3) | ||
| Site of involvement | Right | 10.95 (8.4–13.4) | 0.01 |
| Left | 18.58 (6.1–31.0) | ||
| Bilateral | 1.480 | ||
| Pleural effusion | Yes | 12.03 (5.1–18.9) | 0.80 |
| No | 11.38 (5.1–17.6) | ||
| Pleural effusion | Bilateral | 1.480 | 0.01 |
| Unilateral | 12.03 (5.2–18.8) | ||
| Operation | Yes | 16.51 (11.2–21.7) | 0.14 |
| No | 9.93 (5.9–13.9) | ||
| Chemotherapy | Yes | 17.69 (13.0–22.3) | <0.01 |
| No | 2.82 (0.0–7.8) | ||
| 1st line treatments | Cisplatin/pemetrexed | 18.94 (7.8–30.0) | 0.16 |
| 3M** | 16.51 (10.0–23.0) | ||
| 2nd line treatments | Cisplatin/pemetrexed | 12.00 (6.4–17.5) | 0.02 |
| Cisplatin/gemzar | 18.94 (15.3–22.5) | ||
| 3M | 44.35 (16.4–72.2) |
*
ECOG-PS – Eastern Cooperative Oncology Group-Performance status;
**
3M – mitoxantrone, methotrexate, mitomycine-c.